PDCD1 and ovarian cancer: A recent study showed that the triple blockade of LAG-3, PD-1, and CTLA-4 significantly enhanced antitumor immunity compared with the use of a single anti-PD-1 Ab, resulting in increased cytotoxic T cell levels and reduced Tregs and MDSCs in an ovarian cancer mouse model [66].